References

diaendo

Сахарный диабет

Diabetes mellitus

2072-03512072-0378

Endocrinology research centre

10.14341/2072-0351-5525

diaendo-5525

Research Article

Статьи

Articles

Глимепирид в современной гипогликемизирующей терапии: безопасностьи эффективность

Modern antihyperglycemic therapy: safety and efficacy of glimepiride

Руяткина

Людмила Александровна

Ruyatkina

Lyudmila Alexandrovna

larut@list.ru

Сорокин

Максим Юрьевич

Sorokin

Maksim Yur'evich

ГБОУ ВПО Новосибирский государственный медицинский университет, НовосибирскNovosibirsk State Medical University, Novosibirsk

МБУЗ Городская клиническая больница №1, НовосибирскNovosibirsk City Hospital №1, Novosibirsk

2012

15062012

152

№2 (2012)

8997

2012

Руяткина Л.А., Сорокин М.Ю.

Ruyatkina L.A., Sorokin M.Y.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.dia-endojournals.ru/jour/article/view/5525

Обзор литературы на основе доказательной медицины анализирует фармакологические и клинические аспекты приме-нения глимепирида, определяя место препарата в диалектике современной сахароснижающей терапии с позиций его без-опасности и эффективности, а также кардиопротекции благодаря наличию плейотропных свойств: антиатерогенных,способности корригировать дисфункцию эндотелия и коагуляционный статус, отсутствие угнетения ишемического пре-кондиционирования.

Current review analyzes pharmacological and clinical aspects of glimepiride from perspective of the evidence-based medicine. We aimedto determine position of glimepiride within modern antihyperglycemic dialectics of safety and efficacy. We also address cardioprotectiveproperties of glimeperide due to its anti-atherogenic activity, capacity to correct endothelial dysfunction and hemostatic system, as wellas absence of inhibitory effect on ischemic preconditioning.

сахарный диабет 2 типасульфомочевинаглимепиридкардиопротекциябезопасность сахароснижаю- щей терапии

diabetes mellitus type 2sulphonylureaglimepiridecardioprotectionantihyperglycemic safety

References1

Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes. 2007 Sep;115(8):495-501.

Stamler J, Vaccaro O, Neaton JD, Wetworth D. Diabetes, other risk factors, and 125yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-444.

Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22:1788-1794.

Laakso M, Voutilainen E, Sarlund H, Aro A, Pyorala K, Penttila I. Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics. Atherosclerosis. 1985;56:271-281.

Sharma SC. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile onset and maturity onset diabetes mellitus. J. Pathol. 4 (1981) 501-503.

Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001 Feb 2;88(2):E14-22.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 Sep 18;147(6):386-99

Шведова АМ. Фармакоэпидемиологическая и фармакоэкономическая оценка пероральной сахароснижающей те- рапии сахарного диабета 2 типа в амбулаторной практике. Автореф…. канд. мед. наук. М; 2006. 23 с.

Дедов ИИ, Шестакова МВ, Александров АА, Галстян ГР, Григорян ОР, Есаян РМ, Калашников ВЮ, Кураева ТЛ, Липатов ДВ, Майоров АЮ, Петеркова ВА, Смирнова ОМ, Старостина ЕГ, Суркова ЕВ, Сухарева ОЮ, Токмакова АЮ, Шамхалова МШ, Ярек-Мартынова ИЯ. Алгоритмы специализированной помощи больным сахарным диабетом. Сахарный диабет. 2011;(3): приложение.

Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28(9):426-429.

Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17(6):467-473.

Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000;50(Suppl 1):S47.

Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a noninterventional observational cohort study. Clin Drug Invest 2001;21(9):597-604.

Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M, Runge T. Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations. Final Original Report. Drug Class Reviews. Portland (OR): Oregon Health & Science University; Feb 2011

Davis SN. The role of glimepiride in the effective management of type 2 diabetes. JDiabetes Complications 2004;18(6):367-376.

Leibel B. An analysis of the University Group Diabetes Study Program: data results and conslusions. Can Med Assoc J. 1971 Aug 7;105(3):292-294.

Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32(10):1044-1052.

Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999 Aug;42(8):903-919.

Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochim Biophys Acta. 1994 May 11;1191(2):278-290.

Müller G. The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med. 2000 Nov;6(11):907-933.

Müller G, Hartz D, Pünter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994 May 11;1191(2):267-277.

Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol Drug Interact. 1994;11(4):331-339.

Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004;38(1):30-35.

Matsuki M, Matsuda M, Kohara K, Shimoda M, Kanda Y, Tawaramoto K, Shigetoh M, Kawasaki F, Kotani K, Kaku K. Pharmacokinetics and pharmacody-namics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. Endocr J. 2007 Aug;54(4):571-576.

Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996 Dec; 39(12):1617-1624.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30;329(14):977-986.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.

Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002 Sep;25(9):1607-1611.

Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol. 1998 Jul;38(7):636-641.

Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996;19(8):849-856.

Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996;19(11):1194-1199.

Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD. Shortterm comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997 Jun;31(6):671-676.

Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006;22(4):751-759.

Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995;28(Suppl):S115-137.

Haupt A, Kausch C, Dahl D, Bachmann O, Stumvoll M, Häring HU, Matthaei S. Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. Diabetes Care. 2002 Dec;25(12):2129-2132.

Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J. Diabetes Complicat. 2002;16:123-132.

Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Häring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002 Nov;25(11):2065-2073.

Xu DY, Zhao SP, Huang QX, Du W, Liu YH, Liu L, Xie XM. Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010 Apr;88(1):71-75.

Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a doubleblind comparison with glibenclamide. Horm Metab Res. 1996 Sep;28(9):419-25

Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care. 2003 Feb;26(2):285-289.

Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets. 2012 Jan 11. [Epub ahead of print].

European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, Mc- Donagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Funck-Brentano C, Poldermans D, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769-1818.

Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the antidiabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol. 2008;597(1-3):6-18.

Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabet Complications. 2001;15(Suppl. 1):68.

Агеев ФТ. Роль эндотелиальной дисфункции в развитии и прогрессировании сердечно-сосудистых заболеваний. Сердечная недостаточность. 2003;(4):22.

Durand E, Scoazec A, Lafont A, Boddaert J, Al Hajzen A, Addad F, Mirshahi M, Desnos M, Tedgui A, Mallat Z. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation. 2004 Jun 1;109(21):2503-2506.

Salani B, Repetto S, Cordera R, Maggi D. Glimepiride activates eNOS with a mechanism Akt but not caveolin-1 dependent. Biochem Biophys Res Commun. 2005;335:832-835.

Ueba H, Kuroki M, Hashimoto S, Umemoto T, Yasu T, Ishikawa SE, Saito M, Kawakami M. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis. 2005 Nov;183(1):35-39.

Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase- Akt-dependent pathway. Diabetes Obes Metab. 2009 Feb;11(2):143-149.

Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007 May 1;12:2957-2966.

Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-1251.

Grover GJ, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992 Oct;86(4):1310-1316.

Duncker DJ, Van Zon NS, Altman JD, Pavek TJ, Bache RJ. Role of K+ATP channels in coronary vasodilation during exercise. Circulation. 1993 Sep;88(3):1245-1253.

Pogatsa G, Koltai ZM, Ballagi-Pordany G. Influence of hypoglycemic sulfonylurea compounds on the incidence of ventricular ectopic beats in non-insulin-dependent diabetic patiens treated with digitalis. Curr Ther Res. 1993;53:329-339.

Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res. 1991 Sep;69(3):571-581.

Toombs CF, McGee S, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 1992 Sep;86(3):986-994.

Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse JR 3rd, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J. 1999 Nov;138(5 Pt 1):S376-380.

Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999 Jan;33(1):119-124.

Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001;133(1):193-199.

Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001 Jun 26;103(25):3111-3116.

Caulfield M, O'Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002;20(2):81-84.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203.

Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002 Aug;19(8):673-680.

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001 Oct;18(10):828-834.

Pareek A, Chandurkar NB, Salkar HR, Borkar MS, Tiwari D. Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin. Am J Ther. 2011 Feb 15.

UK Perspective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweigth patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-865.

Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/ metformin therapy over a 7.7-year follow-up. Clin Cardiol. 2001 Feb;24(2):151-158.

Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):477-482.

Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000 May;43(5):558-560.

Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004 May- Jun;20(3):239-245.

Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005 Apr;22(4):497-502.

Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clin Ther. 2009 Nov;31(11):2755-2764.

Gu N, Kim BH, Rhim H, Chung JY, Kim JR, Shin HS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Comparison of the bioa-vailability and tolerability of fixed-dose combination glimepiride/ metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther. 2010 Jul;32(7):1408-1418.

Shin KH, Kim SE, Yoon SH, Cho JY, Jang IJ, Shin SG, Yu KS. Pharmacokinetic comparison of a new sustainedrelease formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Ther. 2011 Nov;33(11):1809-1818.

Baik, SH, Rhim HY, Lee I, Choi DS, Park KS, Song K, Lee K, Cha B, Ahn CW, Lee HW, Chung CH, Nam M, Baek HS, Kim Y, Son H. Comparison of the Efficacy and Safety of fixed dose versus free combination of Glimepiride and Metformin in Patients with type 2 diabetes in Korea. J Med Assoc Thai. 2005;88:245.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009 Nov-Dec;23(6):376-379.

Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, Del Prato S, Marchetti P. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-64.

Kabadi MU, Kabadi UM. Efficacy of sul-fonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother. 2003 Nov;37(11):1572-1576.

Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm Metab Res 1996;28(9):430-433.

Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952-959.

Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J; HOE 901/4013 LA Study Group. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006 May;37(4):495-501.

Kawamori R, Eliaschewitz FG, Takayama H, Hayashida CY. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008 Jan;79(1):97-102

Yokoyama H, Sone H, Yamada D, Honjo J, Haneda M. Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011 Feb;91(2):148-153.

Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):225-235.

Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998;21(7):1052-1057.

Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia. 2010 Aug;53(8):1552-61

Massi-Benedetti M, Herz M, Pfeiffer C. The effect of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 1996; 28: 451-455.

The authors declare that there are no conflicts of interest present.